BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19265858)

  • 1. Inappropriate treatment of prostate cancer caused by heterophilic antibody interference.
    Henry N; Sebe P; Cussenot O
    Nat Clin Pract Urol; 2009 Mar; 6(3):164-7. PubMed ID: 19265858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of metastatic cancer with markedly elevated PSA level that was not detected by repeat prostate biopsy.
    Iwamura H; Hatakeyama S; Tanaka Y; Tanaka T; Tokui N; Yamamoto H; Imai A; Yoneyama T; Hashimoto Y; Koie T; Yoshikawa K; Ohyama C
    BMC Res Notes; 2014 Jan; 7():64. PubMed ID: 24476098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [False Elevation of Prostate-Specific Antigen Caused by Heterophilic Antibody Interference after Radical Prostatectomy : A Case Report].
    Kamiyama Y; Somiya S; Fujikawa S; Yamada Y; Tamaki M; Kanaoka T; Hayashi T
    Hinyokika Kiyo; 2017 Oct; 63(10):435-437. PubMed ID: 29103259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measurements of tissue polypeptide-specific antigen and prostate-specific antigen in prostate cancer patients under intermittent androgen suppression therapy.
    Theyer G; Holub S; Dürer A; Andert S; Haberl I; Theyer U; Hamilton G
    Br J Cancer; 1997; 75(10):1515-8. PubMed ID: 9166947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of locally advanced prostate cancer with low serum testosterone associated with intake of an androgenic medicine].
    Sakura M; Tsukamoto T; Yonese J; Nakaishi M; Maezawa T; Takimoto K; Fukui I
    Nihon Hinyokika Gakkai Zasshi; 2003 May; 94(4):529-32. PubMed ID: 12795169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum heterophile antibodies interfere with prostate specific antigen test and result in over treatment in a patient with prostate cancer.
    Morgan BR; Tarter TH
    J Urol; 2001 Dec; 166(6):2311-2. PubMed ID: 11696766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spurious elevation of serum PSA after curative treatment for prostate cancer: clinical consequences and the role of heterophilic antibodies.
    Anderson CB; Pyle AL; Woodworth A; Cookson MS; Smith JA; Barocas DA
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):182-8. PubMed ID: 22105412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum prostate-specific antigen as a predictor of staging abdominal/pelvic computed tomography in newly diagnosed prostate cancer.
    Huncharek M; Muscat J
    Abdom Imaging; 1996; 21(4):364-7. PubMed ID: 8661585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients.
    Leibowitz RL; Tucker SJ
    Oncologist; 2001; 6(2):177-82. PubMed ID: 11306729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen-all that rises is not refractory.
    Hintz BL; Van Nieuwenhuize A; Kagan AR
    Urology; 2001 May; 57(5):975. PubMed ID: 11337308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Successful complete androgen blockade (CAB) therapy for prostatic cancer detected from multiple lung metastases: a case report].
    Tokumitsu M; Inada F; Kitahara K; Kawakami N; Masui N; Ishida H; Ishida H; Saga Y; Hashimoto H; Yachiku S
    Hinyokika Kiyo; 2001 Jan; 47(1):59-62. PubMed ID: 11235226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early PSA decrease is an independent predictive factor of clinical failure and specific survival in patients with localized prostate cancer treated by radiotherapy with or without androgen deprivation therapy.
    de Crevoisier R; Slimane K; Messai T; Wibault P; Eschwege F; Bossi A; Koscielny S; Bridier A; Massard C; Fizazi K
    Ann Oncol; 2010 Apr; 21(4):808-814. PubMed ID: 19825885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial.
    Carrie C; Hasbini A; de Laroche G; Richaud P; Guerif S; Latorzeff I; Supiot S; Bosset M; Lagrange JL; Beckendorf V; Lesaunier F; Dubray B; Wagner JP; N'Guyen TD; Suchaud JP; Créhange G; Barbier N; Habibian M; Ferlay C; Fourneret P; Ruffion A; Dussart S
    Lancet Oncol; 2016 Jun; 17(6):747-756. PubMed ID: 27160475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen half-life and pretreatment prostate-specific antigen: crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy.
    Soga N; Onishi T; Arima K; Sugimura Y
    Int J Urol; 2007 Mar; 14(3):192-6; discussion 197. PubMed ID: 17430253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal therapy for patients with advanced adenocarcinoma of the prostate: is there a role for discontinuing treatment after prolonged androgen suppression?
    Pedraza R; Kwart AM
    Urology; 2003 Apr; 61(4):770-3. PubMed ID: 12670563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes of androgen deprivation as the sole therapy for localized and locally advanced prostate cancer.
    Janoff DM; Peterson C; Mongoue-Tchokote S; Peters L; Beer TM; Wersinger EM; Mori M; Garzotto M
    BJU Int; 2005 Sep; 96(4):503-7. PubMed ID: 16104900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elevated serum chromogranin A precedes prostate-specific antigen elevation and predicts failure of androgen deprivation therapy in patients with advanced prostate cancer.
    Chuang CK; Wu TL; Tsao KC; Liao SK
    J Formos Med Assoc; 2003 Jul; 102(7):480-5. PubMed ID: 14517586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False elevations in prostate-specific antigen levels affecting patient management.
    Kummar S; Shafi NQ
    Clin Adv Hematol Oncol; 2004 Sep; 2(9):599-601; discussion 602. PubMed ID: 16163243
    [No Abstract]   [Full Text] [Related]  

  • 20. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
    McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
    Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.